Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Implementation of quality improvement intervention reduces medication use in premature babies: Study

A new study by Pediatrix Medical Group researchers has found that the implementation of a quality improvement intervention significantly reduces the use of a large number of medications in premature babies across a broad neonatal intensive care network.

3 May 2010

NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay Pharmaceuticals, Inc. announced today that the latest public data on its Aganocide® compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology annual meeting in Fort Lauderdale, Florida.

30 Apr 2010

Data mining of hospital information can help identify MDROs: Asolva

Infection control within hospitals is a huge and growing problem. A recent study in the Archives of Internal Medicine found that conditions caused by healthcare associated infections killed 48,000 people and increased healthcare costs by $8.1 billion in 2006 alone.

30 Apr 2010

miacom diagnostics announces new tests for faster diagnosis of sepsis

"Conventional PCR tests (PCR is short for polymerase chain reaction, a highly sensitive method of detecting nucleic acids) require several hours to produce a result. lucesco Bacteremia IVD panels are not only much faster with a result after only 30 minutes, they are also much more cost-efficient.

29 Apr 2010

Cambodia closes 64.9 percent of illegal pharmacies

In a major crackdown, Cambodia has forced nearly 65 percent of illegal pharmacies operating in the country to close within the past five months. Led by an Inter-Ministerial Committee to Fight against Counterfeit & Substandard Medicines (IMC), the shops were targeted because of evidence that they were among the primary sources of substandard and counterfeit medicines in the country.

29 Apr 2010

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination antibiotics effectively treat Chlamydia-induced reactive arthritis - a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

29 Apr 2010

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that it will be presenting three separate presentations at the Cambridge Healthtech Institute's 4th Annual Antibacterial Drug Development Conference, Resistance is Futile: The Challenge of Antibacterial Drug Development, April 27 - 28, in San Diego, CA.

27 Apr 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

Fever in kids underestimated by Doctors: new study

In a new study researchers have found that some physicians may be missing the seriousness of an infection in a child presenting with fever. The study published in the British Medical Journal involved 16,000 children from 2004 to 2006 with fever and found that doctors could not diagnose up to one third of the potentially life-threatening illnesses in these children.

27 Apr 2010

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor's novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.

26 Apr 2010

Driving evolution of antibiotic resistance backwards

The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.

26 Apr 2010

New method helps study interactions needed for formation of lipopolysaccharides

Scientists have combined chemistry and biology research techniques to explain how certain bacteria grow structures on their surfaces that allow them to simultaneously cause illness and protect themselves from the body's defenses.

26 Apr 2010

McGill researchers receive $1.7M for 10 cutting-edge research projects

Ten McGill University researchers received an important boost today, by way of the announcement of $1.7 million in new funding awarded through the Canada Foundation for Innovation's Leaders Opportunity Fund. "CFI investments are critical for our research leaders, to ensure that their research remains innovative and second to none," said Dr. Rima Rozen, Interim Vice-Principal (Research and International Relations) at McGill.

24 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

Complaint regarding Dragon Pharma's proposed merger with Datong Investment filed

Dragon Pharmaceutical Inc. announced today that a complaint regarding its proposed merger with Datong Investment Inc was filed in the Circuit Court of the Fifteenth Judicial Circuit for Palm Beach County, State of Florida, against the Company, and its eight directors.

23 Apr 2010

Dehaier Medical Systems announces initial public offering

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today its initial public offering of 1,500,000 ordinary shares at $8.00 per share. The ordinary shares will begin trading today under the ticker symbol "DHRM" on the Nasdaq Capital Market.

23 Apr 2010

Acacia Research reports record first-quarter license fee revenues of $39.77M

Acacia Research Corporation today reported results for the three months ended March 31, 2010.

23 Apr 2010

Antibiotic News and Research

Further Reading

Implementation of quality improvement intervention reduces medication use in premature babies: Study

NovaBay to present data on Aganocide compounds at ARVO annual meeting

Data mining of hospital information can help identify MDROs: Asolva

miacom diagnostics announces new tests for faster diagnosis of sepsis

Cambodia closes 64.9 percent of illegal pharmacies

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Rib-X Pharmaceuticals to demonstrate three presentations at Antibacterial Drug Development Conference

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

Fever in kids underestimated by Doctors: new study

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Driving evolution of antibiotic resistance backwards

New method helps study interactions needed for formation of lipopolysaccharides

McGill researchers receive $1.7M for 10 cutting-edge research projects

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Complaint regarding Dragon Pharma's proposed merger with Datong Investment filed

Dehaier Medical Systems announces initial public offering

Acacia Research reports record first-quarter license fee revenues of $39.77M

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News